On Tuesday, Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide.  This approval sets the stage for heightened competition with Novo Nordisk A/S (NYSE:NVO) in the crucial Asian market.  Tirzepatide, known in the U.S. under the brand names Mounjaro for diabetes and Zepbound for weight loss, will now be used in China to treat adults with type 2 diabetes. Also Read: Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro. This development comes as Novo Nordisk’s diabetes drug Ozempic, approved in China in 2021, has seen significant sales growth in the region.  Novo Nordisk’s ...